Department of Nutrition and Dietetics (DND), Institute of Nutrition Josué de Castro, Federal University of Rio de Janeiro, Rio de Janeiro - RJ, Brazil.
Lebiome - Núcleo de estudos com bioativos, Mitocôndria e metabolismo da placenta, Institute of Nutrition Josué de Castro, Federal University of Rio de Janeiro, Rio de Janeiro - RJ, Brazil.
Food Funct. 2021 Mar 15;12(5):2161-2170. doi: 10.1039/d0fo02748k.
Modulation of the gut microbiota may help in treating obesity by improving host metabolic health. We aimed to evaluate the effects of probiotics or symbiotics on body weight and serum metabolite profile in women with obesity. A double-blind, parallel, randomized, controlled clinical trial was conducted with 32 adult women with body mass index ranging from 30 to 34.9 kg m-2. Volunteers followed a low-energy diet and were subjected to 8 weeks intervention: probiotic group (PG - Bifidobacterium lactis UBBLa-70, n = 10), symbiotic group (SG - Bifidobacterium lactis UBBLa-70 and fructooligosaccharide, n = 11), or control group (CG - placebo, n = 11). Analyses of anthropometric variables, gut microbiota and serum metabolites by 1H nuclear magnetic resonance (NMR) were performed at baseline and after the intervention. Multivariate statistics showed that all groups presented a decrease in glycerol and increase in arginine, glutamine and 2-oxoisovalerate. Therefore, a low-energy diet per se promoted changes in the metabolite profile related to decreased inflammation and positive effects on body weight. SG presented unique changes in metabolites (increase in pyruvate and alanine and decrease in citrate and BCAA). Negative correlations between arginine and glutamine with fat mass were observed in the SG. PG presented a decrease in 1H NMR lipid signals and negative correlation between Verrucomicrobia and Firmicutes with (CH2)n lipids. Both probiotics and symbiotics promoted changes in metabolites related to improved metabolic health. Specific metabolite changes following symbiotic intervention might suggest some advantage in providing Bifidobacterium lactis in combination with fructooligosaccharide in a low-energy diet, rather than probiotics or diet alone. Clinical trial: NCT02505854.
肠道微生物群的调节可能有助于通过改善宿主代谢健康来治疗肥胖。我们旨在评估益生菌或共生菌对肥胖女性体重和血清代谢物谱的影响。进行了一项双盲、平行、随机、对照临床试验，纳入了 32 名体重指数在 30 至 34.9 kg/m2 之间的成年肥胖女性。志愿者遵循低能量饮食，并接受 8 周的干预：益生菌组（PG - 乳双歧杆菌 UBBLa-70，n = 10）、共生组（SG - 乳双歧杆菌 UBBLa-70 和低聚果糖，n = 11）或对照组（CG - 安慰剂，n = 11）。在基线和干预后，通过 1H 核磁共振（NMR）分析人体测量变量、肠道微生物群和血清代谢物。多变量统计显示，所有组的甘油水平均降低，精氨酸、谷氨酰胺和 2-氧异戊酸水平均升高。因此，低能量饮食本身促进了与炎症减轻和体重积极影响相关的代谢物谱的变化。SG 呈现出独特的代谢物变化（丙酮酸和丙氨酸增加，柠檬酸和支链氨基酸减少）。在 SG 中观察到精氨酸和谷氨酰胺与脂肪质量之间存在负相关。PG 呈现出 1H NMR 脂质信号减少，拟杆菌门和厚壁菌门与（CH2）n 脂质之间存在负相关。益生菌和共生菌都促进了与改善代谢健康相关的代谢物的变化。共生干预后特定代谢物的变化可能表明，在低能量饮食中添加低聚果糖与乳双歧杆菌联合使用，比益生菌或饮食单独使用更具优势。临床试验：NCT02505854。
